Abstract：
OBJECTIVE: Advanced clear cell renal cell carcinoma (ccRCC) seriously affects the life and health of patients, but effective treatment for this disease is still lacking in clinic. This study investigated the efficacy of nivolumab plus cabozantinib versus sunitinib in the treatment of elderly patients with advanced ccRCC.
METHODS: The clinical data of 216 elderly patients with advanced ccRCC in our hospital from January 2020 to January 2022 were retrospectively analysed. On the basis of different treatment regimens, patients were divided into the cabozantinib group (n = 111, receiving nivolumab and cabozantinib) and the sunitinib group (n = 105, receiving nivolumab and sunitinib). The overall survival time, disease control rates, health status, incidence of adverse events and identification of prognostic risk were compared between the two groups.
RESULTS: The cabozantinib group had higher overall survival time, disease control rate and scores in the Functional Assessment of Cancer Therapy-Kidney Symptom Index and EuroQol-Five Dimensions-Three Levels Questionnaire than the sunitinib group. The incidence of adverse events in the cabozantinib group was lower than that in the sunitinib group (p < 0.001). However, no difference existed in the identification of prognostic risk between the two groups (p > 0.05).
CONCLUSIONS: The effect of nivolumab plus cabozantinib on the treatment of elderly patients with advanced ccRCC is better than that of nivolumab plus sunitinib, with fewer adverse reactions and higher safety. However, the research results require further clinical studies to confirm and promote.
METHODS: The clinical data of 216 elderly patients with advanced ccRCC in our hospital from January 2020 to January 2022 were retrospectively analysed. On the basis of different treatment regimens, patients were divided into the cabozantinib group (n = 111, receiving nivolumab and cabozantinib) and the sunitinib group (n = 105, receiving nivolumab and sunitinib). The overall survival time, disease control rates, health status, incidence of adverse events and identification of prognostic risk were compared between the two groups.
RESULTS: The cabozantinib group had higher overall survival time, disease control rate and scores in the Functional Assessment of Cancer Therapy-Kidney Symptom Index and EuroQol-Five Dimensions-Three Levels Questionnaire than the sunitinib group. The incidence of adverse events in the cabozantinib group was lower than that in the sunitinib group (p < 0.001). However, no difference existed in the identification of prognostic risk between the two groups (p > 0.05).
CONCLUSIONS: The effect of nivolumab plus cabozantinib on the treatment of elderly patients with advanced ccRCC is better than that of nivolumab plus sunitinib, with fewer adverse reactions and higher safety. However, the research results require further clinical studies to confirm and promote.
摘要：
目的:晚期肾透明细胞癌(ccRCC)严重影响患者的生命健康,但是这种疾病的有效治疗在临床上仍然缺乏。本研究探讨了纳武单抗联合卡博替尼与舒尼替尼治疗老年晚期ccRCC的疗效。
方法：回顾性分析我院2020年1月至2022年1月216例老年晚期ccRCC患者的临床资料。根据不同的治疗方案，患者被分为卡博替尼组(n=111,接受纳武单抗和卡博替尼)和舒尼替尼组(n=105,接受纳武单抗和舒尼替尼).总生存时间,疾病控制率,健康状况,比较两组患者的不良事件发生率和预后风险.
结果：卡博替尼组的总生存时间更长，癌症治疗功能评估-肾脏症状指数和EuroQol-五维度-三级问卷的疾病控制率和评分高于舒尼替尼组。卡博替尼组的不良事件发生率低于舒尼替尼组(p<0.001)。然而,两组间对预后风险的判断差异无统计学意义(p>0.05)。
结论：纳武单抗联合卡博替尼治疗老年晚期ccRCC的效果优于纳武单抗联合舒尼替尼，不良反应少，安全性高。然而,研究结果需要进一步的临床研究来证实和推广。
方法：回顾性分析我院2020年1月至2022年1月216例老年晚期ccRCC患者的临床资料。根据不同的治疗方案，患者被分为卡博替尼组(n=111,接受纳武单抗和卡博替尼)和舒尼替尼组(n=105,接受纳武单抗和舒尼替尼).总生存时间,疾病控制率,健康状况,比较两组患者的不良事件发生率和预后风险.
结果：卡博替尼组的总生存时间更长，癌症治疗功能评估-肾脏症状指数和EuroQol-五维度-三级问卷的疾病控制率和评分高于舒尼替尼组。卡博替尼组的不良事件发生率低于舒尼替尼组(p<0.001)。然而,两组间对预后风险的判断差异无统计学意义(p>0.05)。
结论：纳武单抗联合卡博替尼治疗老年晚期ccRCC的效果优于纳武单抗联合舒尼替尼，不良反应少，安全性高。然而,研究结果需要进一步的临床研究来证实和推广。
